Welcome to our dedicated page for Bright Minds Biosciences SEC filings (Ticker: DRUG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bright Minds Biosciences Inc. (DRUG) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer under Commission File No. 001-40997. Bright Minds files reports on Form 6-K to furnish material information to U.S. investors, including clinical updates, financing transactions, interim financial statements and other significant developments related to its biotechnology business focused on neurological and psychiatric disorders.
Among the filings, investors can find Form 6-K reports describing public offerings of common shares made under shelf registration statements on Form F-3. A January 8, 2026 Form 6-K outlines an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC, Piper Sandler & Co., and Cantor Fitzgerald & Co. for an underwritten public offering of 1,945,000 common shares. The filing details gross proceeds, the underwriters’ option to purchase additional shares, and the company’s stated intention to use net proceeds to fund clinical trials in absence seizures, DEE and Prader-Willi Syndrome, initiate Phase 1 trials for BMB-105, support earlier-stage research and development, and for general corporate and working capital purposes.
Other 6-K submissions incorporate news releases by reference, such as announcements on the initiation of the Prader-Willi Syndrome program, expansion of the scientific advisory board, and positive Phase 2 data for BMB-101. Bright Minds also uses Form 6-K to file condensed interim consolidated financial statements, management’s discussion and analysis, and related CEO and CFO certifications, which are incorporated by reference into its Form F-3 registration statements.
On Stock Titan, these filings are complemented by AI-powered summaries that help explain the key points of lengthy documents, including shelf registrations, underwriting agreements and clinical disclosures. Users can quickly identify how new filings affect Bright Minds’ capital structure, clinical plans and risk profile, and can review exhibits such as legal opinions and consent letters that accompany major financing transactions.
Janus Henderson Group plc filed an amended Schedule 13G/A reporting beneficial ownership of 1,155,995 shares of Bright Minds Biosciences Inc. common stock, or 14.9% of the class, as of 12/31/2025.
The shares are held across various Janus Henderson asset management subsidiaries in managed client accounts, with Janus Henderson reporting shared power to vote and dispose of all 1,155,995 shares and no sole voting or dispositive power. The filing states the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of Bright Minds Biosciences.
Bright Minds Biosciences Inc. received an updated ownership report from Commodore Capital. Commodore Capital LP and Commodore Capital Master LP filed Amendment No. 2 to a Schedule 13G/A reporting beneficial ownership of 18,851 common shares, representing about 0.3% of Bright Minds’ outstanding common shares.
The filing states that Commodore Capital, as investment manager to Commodore Capital Master LP, may be deemed to beneficially own these securities, with shared voting and dispositive power over all reported shares. The ownership percentage is based on 7,635,789 common shares outstanding as of September 30, 2025.
The signatory certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Bright Minds Biosciences Inc., but instead under a passive investment intent consistent with Schedule 13G requirements.
Bright Minds Biosciences Inc. received an amended Schedule 13G showing that Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. jointly report beneficial ownership of 449,290 common shares, or 4.6% of the class. This percentage is based on 9,732,161 common shares outstanding as reported in a recent prospectus supplement. The filing states the securities are not held for the purpose of changing or influencing control of the company.
Bright Minds Biosciences reported a net loss of $7.6 million for the quarter ended December 31, 2025, compared with net income of $49,610 a year earlier, as it sharply increased research and development spending.
R&D expenses rose to $5.7 million from $1.0 million, driven by expanded clinical and preclinical work and higher share-based compensation. Despite the loss, the company held $89.0 million in cash and cash equivalents and working capital of $89.2 million, and raised $13.9 million via its at-the-market program during the quarter.
Subsequently, on January 9, 2026, Bright Minds completed a public offering of 1,945,000 common shares at US$90.00 per share for gross proceeds of about US$175.1 million, further strengthening its funding for ongoing and planned trials of lead epilepsy candidate BMB-101 and other 5-HT2 programs.
Cormorant Asset Management LP and Bihua Chen report beneficial ownership of 1,059,331 Bright Minds Biosciences common shares, representing 10.88% of the class. All voting and dispositive power over these shares is shared, with no sole authority reported.
The shares are held through Cormorant Global Healthcare Master Fund, LP and related Cormorant funds. The filers state the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Bright Minds Biosciences.
Bright Minds Biosciences Inc. closed a public offering of 1,945,000 common shares at US$90.00 per share, resulting in gross proceeds of US$175,050,000. The company also granted underwriters a 30-day option to buy up to an additional 291,750 common shares at the same public offering price, less underwriting discounts and commissions.
All securities in this offering were sold by Bright Minds. The company plans to use the net proceeds to fund future clinical trials for its drug candidates in absence seizures, developmental and epileptic encephalopathies, and Prader-Willi Syndrome, to initiate phase 1 clinical trials for BMB-105, to support earlier-stage research and development programs, and for general corporate and working capital purposes.
Bright Minds Biosciences Inc. entered into an underwriting agreement to sell 1,945,000 common shares at $90.00 per share, for gross proceeds of $175,050,000 in an underwritten public offering. The company expects net proceeds of approximately $164,372,000, or approximately $189,054,050 if the underwriters fully exercise their option to purchase up to an additional 291,750 common shares.
The offering is expected to close on January 9, 2026 and was made under the company’s effective Form F-3 shelf registration statements. Bright Minds plans to use the funds to support future clinical trials for drug candidates targeting absence seizures, developmental and epileptic encephalopathies, and Prader-Willi Syndrome, to initiate phase 1 trials for BMB-105, to advance earlier-stage research programs, and for general corporate and working capital purposes.
Bright Minds Biosciences Inc. is conducting a primary public offering of 1,945,000 common shares at $90.00 per share, for gross proceeds of $175,050,000. After underwriting discounts and estimated expenses, the company expects net proceeds of about $164,372,000, and has granted underwriters a 30‑day option for up to an additional 291,750 shares.
Common shares outstanding are expected to rise to 9,732,161 (or 10,023,911 if the option is fully exercised) from 7,787,161 as of the prospectus date, meaning existing holders will be diluted. Bright Minds plans to use the funds to advance clinical trials for drug candidates in absence epilepsy, DEE, Prader‑Willi Syndrome, initiate phase 1 trials for BMB‑105, support earlier‑stage R&D programs and for general corporate purposes. The company warns that this is a high‑risk investment and highlights potential volatility, future capital needs and possible NASDAQ listing risks.
Bright Minds Biosciences Inc. is pricing an upsized public offering of 1,945,000 common shares at $90.00 per share for anticipated gross proceeds of $175,050,000. Underwriters have a 30-day option to buy up to an additional 291,750 shares at the public offering price, and all shares are being sold by the company. Closing is expected on January 9, 2026, subject to customary conditions.
Bright Minds plans to use the net proceeds to fund future clinical trials for its drug candidates, including programs for absence seizures, developmental and epileptic encephalopathies, and Prader-Willi Syndrome, as well as to start phase 1 trials for BMB-105 and advance earlier-stage research. Remaining funds are earmarked for general corporate and working capital purposes. In connection with this deal, the company terminated a prior at-the-market equity program that had allowed up to US$100 million of share sales.
Bright Minds Biosciences Inc. reports that, on January 7, 2026, it mutually agreed with Piper Sandler & Co. and Cantor Fitzgerald & Co. to terminate their Equity Distribution Agreement dated August 25, 2025, effective the same day. This agreement had allowed the company to distribute equity through these firms, and its termination ends that arrangement.
The company also notes that this disclosure is incorporated by reference into its registration statements on Form F-3 with file numbers 333-284694 and 333-289851.